Cognition Therapeutics, Inc. is facing a potential delisting from the Nasdaq Stock Market after its stock price fell below the required minimum of $1.00 per share. The company received a deficiency letter from Nasdaq on November 3, 2026, indicating that its common stock had not met the minimum bid price requirement for 30 consecutive business days. This situation is significant as it highlights the ongoing challenges faced by emerging growth companies in the biological products sector.
According to the recent SEC filing, Cognition Therapeutics, which trades under the ticker symbol CGTX, has been granted a 180-day period to regain compliance with Nasdaq Listing Rule 5450(a)(1). If the company can raise its stock price to $1.00 or more for ten consecutive business days before May 3, 2027, it will be considered compliant. Until then, the stock will continue to trade on the Nasdaq.
Background
Cognition Therapeutics, Inc., incorporated in Delaware, specializes in developing therapies for neurodegenerative diseases. The company operates under the Standard Industrial Classification of Biological Products (No Diagnostic Substances) [2836]. It is classified as an emerging growth company and trades on the Nasdaq exchange under the ticker CGTX. The company has been active in filing various forms with the SEC, including recent 8-K filings regarding its financial condition and operations.
What the Filing Says
The SEC filing, dated November 5, 2026, states, "The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s common stock, and its common stock will continue to trade on Nasdaq Capital Market under the symbol 'CGTX' at this time." Cognition Therapeutics has until May 3, 2027, to regain compliance with the minimum bid price requirement.
Impact
This situation may affect investors and stakeholders in Cognition Therapeutics as they monitor the company’s stock performance closely. The company’s ability to regain compliance is crucial not only for maintaining its listing but also for its overall market perception and investor confidence.
What's Next
The company intends to actively monitor its stock price and explore options to resolve the deficiency. However, the filing does not specify any immediate actions that will be taken beyond this monitoring.
Read Next
Ronald N. Tutor sells 150,000 shares of Tutor Perini Corp.
Generation Income Properties reports Q3 2026 results
Greenlane Holdings reports Q3 2026 results amid challenges
Permianville Royalty Trust Reports Q3 Financial Results
Cue Biopharma Reports Q3 Results with Financial Insights
Atlantica Inc Reports Q3 Results, Highlights Financial Updates










